# OnCo record alphamab (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/alphamab/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "alphamab" ;
  schema:name "Alphamab Oncology"@en ;
  schema:alternateName "康宁杰瑞"@en, "Jiangsu Alphamab Biopharmaceuticals"@en, "Alphamab Oncology"@en ;
  schema:description "Alphamab developed envafolimab, the first subcutaneous PD-L1 antibody approved anywhere, and the HER2 bispecific ADC JSKN003."@en ;
  schema:url <https://onco.cc/companies/alphamab/>, <https://www.alphamabonc.com/en/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.alphamabonc.com/en/> ;
  onco:tag "china" ;
  schema:addressCountry "CN" ;
  onco:sections <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/adcs/> ;
  onco:targets <https://onco.cc/targets/her2/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/envafolimab/>, <https://onco.cc/drugs/jskn003/>, <https://onco.cc/drugs/jskn016/> ;
  onco:trials <https://onco.cc/trials/nct06942234/>, <https://onco.cc/trials/nct05744427/> .